ML 145 是一种选择性和竞争性的人 GPR35/CXCR8 拮抗剂,IC50/EC50 为 20.1 nM。
Cas No. | 1164500-72-4 |
化学名 | 2-hydroxy-4-((Z)-(1-hydroxy-4-((Z)-5-((E)-2-methyl-3-phenylallylidene)-4-oxo-2-thioxothiazolidin-3-yl)butylidene)amino)benzoic acid |
Canonical SMILES | CC(/C([H])=C(S1)/C(N(C1=S)CCC/C(O)=N/C2=CC(O)=C(C(O)=O)C=C2)=O)=C([H])\C3=CC=CC=C3 |
分子式 | C24H22N2O5S2 |
分子量 | 482.57 |
溶解度 | <48.26mg/ml in DMSO |
储存条件 | Store at -20°C |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | ML 145 is a selective GPR35/CXCR8 antagonist with an IC50/EC50 of 20.1 nM, but not for the related GPR55 orphan receptor[1]. GPR35 is expressed by various cells of the immune system and it may has potential as a therapeutic target in inflammatory disease[2]. References: [1]. Heynen-Genel S, et al. Selective GPR35 Antagonists - Probes 1 & 2. National Center for Biotechnology Information (US); 2010-2010 Feb 28. [2]. Binti Mohd Amir NAS, et al. Evidence for the Existence of a CXCL17 Receptor Distinct from GPR35. J Immunol. 2018 Jul 15;201(2):714-724. |